Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

LSN Announces Collaboration with Government of Ontario and Ontario Bioscience Innovation Organization (OBIO) at RESI Boston in September

17 Aug

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Life Science Nation (LSN) is thrilled to be collaborating with the Government of Ontario and Ontario Bioscience Innovation Organization (OBIO) at the Redefining Early Stage Investments (RESI) conference, scheduled to take place from September 18-20 at the Boston Park Plaza. The first day will consist of in-person partnering, panels, pitches, and workshops, followed by two virtual partnering days. This collaboration brings together three influential organizations who are tackling the life sciences arena and aims to foster an ecosystem where innovation is nurtured and capital flows seamlessly in Ontario, Canada.

As part of this collaboration, the Government of Ontario and OBIO will be featuring a group of 15 early-stage startups to showcase the latest advancements across:

  1. Nutrition
  2. Polyphenols to treat chronic diseases
  3. Robotic intramuscular injections
  4. Wearable artificial kidney for ambulatory dialysis
  5. Therapies and solutions in HDAC-driven pathologies, surgical oncology, complex inflammatory skin diseases, and onychomycosis
  6. Electronic medical records
  7. Non-viral and re-dosable gene therapies

Ontario Companies

These entrepreneurs will be provided with a unique platform to present their disruptive technologies, engage in one-on-one discussions with potential investors seeking to catalyze growth and expedite the journey toward impactful biotechnological breakthroughs.

With their unique and collaborative innovation ecosystem, Ontario is where companies come to grow and prosper. The same innovative spirit that led to the discovery of insulin in Ontario one hundred years ago has led to game-changing technologies such as 3D bioprinters and techniques to boost stem cell renewal. Whether you want to expand your operations here or source some of the highest quality medical products and services in the world, Ontario is your life sciences destination.

Get ready to meet the 15 startups and staff from Government of Ontario and OBIO at RESI Boston in September!

RESI-Boston-2023-September-1100px-w

Surge in Family Offices: Investing in Healthcare

10 Aug

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

In the ever-evolving finance and investment landscape, family offices have emerged as key players with the potential to drive significant change. These private wealth management firms, entrusted with managing the financial affairs of affluent families, have diversified their portfolios to include investments in a wide array of sectors. One sector that has garnered substantial attention in recent years is healthcare. The intersection of wealth preservation, a family’s medical health profile, and social impact have led many family offices to focus on investing in healthcare, a decision that promises financial returns, improves family legacy, and impacts global well-being.

LSN Collaboration with Stetson Family Office in 2019

LSN launched the Global Family Office BioForum in 2019 in collaboration with the Stetson Family Office to match Family Offices with angel groups, early-stage VCs, and KOLs to help identify and vet early-stage healthcare investment opportunities.  This collaboration was an extension of Chuck Stetson’s visionary initiative on educating family offices to understand how they can impact chronic diseases like Alzheimer’s, Cancer, and Diabetes/Obesity and tackle big global healthcare issues through his Healthcare Impact Foundation. Over the years, the Global Family Office BioForum has witnessed many of these relationships fostered at LSN’s RESI partnering events grow into strategic alliances and investment syndicates that have helped Family Offices move into the early stage healthcare arena.

The Dynamics of Family Offices

Family offices, by their structure, cater to the unique financial needs of high-net-worth families. With a long-term perspective, they prioritize wealth preservation, growth, and the passing down of wealth to future generations. This approach aligns well with the characteristics of the healthcare sector, which, given its essential nature, presents a range of investment opportunities with the potential for both social impact and financial gains. New drug development can take a decade or more and cost hundreds of millions of dollars, while devices, diagnostics, and digital health technology can be developed in three to five years for five to 15 million.  This breadth of choice allows a family office to execute its financial, healthcare, and social impact goals.

Why Healthcare?

As I have stated in the past, planet Earth is in the golden age of life science. Like other investor classes, family offices want a high return rate based on a timeline that matches their money management goals.   The healthcare industry is undergoing rapid transformation, driven by technological advancements, changing demographics, and evolving consumer expectations. These shifts create fertile ground for investment, with opportunities that span pharmaceuticals, biotechnology, medical devices, telemedicine, healthcare IT, and more. The demand for innovative solutions to global health challenges is greater than ever, and family offices are positioning themselves as key contributors to this transformation.

Balancing Profit and Purpose

Family offices are uniquely positioned to balance profit with purpose. Investing in healthcare allows them to pursue financial returns and contribute to improving healthcare access, quality, and affordability. Many family offices see healthcare investments to align their financial goals with their desire to positively enhance their family legacy and society.

Driving Innovation

One of the remarkable aspects of family offices’ involvement in healthcare is their ability to drive innovation. By injecting capital into early-stage startups and research initiatives, family offices provide crucial support to ventures that may otherwise struggle to secure funding. This backing accelerates the development of groundbreaking therapies, technologies, and services, ultimately benefiting patients worldwide.

RESI-Boston-2023-September-1100px-w

Announcing the Global Partnering Campaign, LSN’s Newest Product

10 Aug

By Karen Deyo, Director of Product, Israel BD, LSN

Life Science Nation (LSN) is excited to announce that our newest product, the Global Partnering Campaign Salesforce App, is live! This is a new way to access the LSN Investor and Licensing Partner Database, taking the benefits of LSN’s curated data (10 categories of investors from 3,000 firms with 10,000 contacts), and combining it with LSN’s custom-developed fundraising campaign management tool.

What is the difference between the LSN Investor and Licensing Partner Database and the new GPC product?

The GPC product is a Salesforce App that has to be downloaded off of the Salesforce AppExchange and installed into the company’s Salesforce account. The LSN Investor and Licensing Partner Database gives you access to the same content without a subscription to Salesforce.

Do I need to subscribe to Salesforce to use the new GPC product?

Yes, this new product is available through Salesforce only. Using a CRM like Salesforce is a crucial tool for managing a fundraising campaign and tracking all of your contact with investors and licensing partners – ensuring no missed opportunities or dropped balls.

What do I need to do to get the GPC App?

If you are not already a Salesforce client, subscribe to Salesforce (Professional license or above required), go the Salesforce AppExchange, and find and install the Life Science Nation – Global Partnering Campaign (GPC) app. Once you have installed the app, you will need to subscribe to the Essential or Premium plan through this link and contact LSN at gpc@lifesciencenation.com for your onboarding with your BD representative. After the onboarding is complete, LSN staff will activate the GPC app, and you can start identifying your Global Target List of investors and licensing partners and begin your outreach!

Click here to watch a demo of the new product!

RESI-Boston-2023-September-1100px-w

Interview with Shikha Sharma, Senior Director, Innovation at California Life Sciences (CLS)

10 Aug
Shikha-SharmaShikha Sharma Interview with Shikha Sharma, Senior Director, Innovation at California Life Sciences

By Caitlin Dolegowski, Marketing Manager, LSN

 CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): Please introduce us to California Life Sciences.

Shikha Sharma (SS): California Life Sciences (CLS) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For more than 30 years, CLS has served the community by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. On behalf of our more than 1,200 member organizations, CLS works to shape public policy, improve access to breakthrough technologies, educate lawmakers, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. In doing so, CLS fulfills its mission to protect and nurture California’s life sciences industry, empowering discoveries that lead to healthier lives around the world.

CD: What type of companies do California Life Sciences consider for membership?

SS: CLS members represent companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector.

CD: What stage of fundraising is California Life Sciences looking to support?

SS: The CLS Innovation & Entrepreneurship programs primarily support early-stage companies in fundraising stages from pre-seed to Series A. However, the broader CLS community encompasses members, companies, stakeholders, and pharma industry professionals with accessibility to later stage fundraising know-how and connections. Becoming part of CLS gives you access to a broad network that can directly and indirectly support companies in any stage of fundraising.

CD: Clearly, California Life Sciences, is in California. Though, not all your members are located in California. What are your geographic qualifications?

SS: We don’t have geographic qualifications, per se.  CLS welcomes any organization that is looking to access, expand and/or maintain a foothold in what I would consider the most robust life sciences ecosystem worldwide.

CD: What works well for California Life Sciences in being a part of the RESI experience?

SS: As part of our portfolio of entrepreneurship services, CLS seeks to establish partnerships with respected partnering and investor conferences to aid our members in the fundraising journeys. Importantly, opportunities like RESI connects them with Seed and Series B investors, channel and licensing partners.

CD: What other information is important for companies to consider about California Life Sciences?

SS:  California Life Sciences’ innovation and entrepreneurship initiatives connect life science startups to the resources needed to help them effectively scale their ventures. Our programs create a platform for accessing business partners, investors, foundations and patient advocacy organizations, peers, and other industry leaders.

Designed to nurture and advocate for emerging and diverse innovators from throughout the state, CLS offers advisory services, positioning for capital tools, access to capital through strategic partnerships and events and US market access resources to help in the development and commercialization of their business.

RESI-Boston-2023-September-1100px-w

Apply before August 9 and Join these Confirmed Companies at RESI September Innovator’s Pitch Challenge (IPC)

3 Aug

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

Life Science Nation (LSN)’s next event, RESI September, is coming up on September 18. The conference will take place at the Boston Park Plaza, located in the heart of Boston – a hub of life science and healthcare innovation.

RESI has consistently provided an exceptional opportunity for entrepreneurs to pitch directly to a panel of active investors and industry experts through the Innovator’s Pitch Challenge (IPC). The IPC has rapidly gained popularity and has become the go-to event for many successful entrepreneurs to fine-tune their pitching skills, receive valuable feedback on their products and technologies and connect directly with seasoned investors.

During an IPC session, participating companies will be given 4 minutes for their presentation, followed by 9 minutes of Q&A. IPC’s unique format and judge recruitment process allows companies to pitch alongside fellow entrepreneurs operating in the same sectors and in front of a panel of investor pitch judges who are immensely experienced in that particular sector. By joining the IPC, companies gain not only significant exposure, but also invaluable connections with influential investors and industry experts.

We are excited to announce a selection of the confirmed companies that will be pitching at RESI September. Don’t forget to submit your application before the deadline on August 9 to join these companies at RESI September IPC.

Confirmed Pitch Companies
And More…

RESI-Boston-2023-September-1100px-w

Exhibiting at RESI Boston September 2023

3 Aug

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI is returning to Boston in September and will be in-person on September 18, with a hybrid digital component on September 19-20. The feedback from exhibitors at our recent conferences has been amazing. The opportunity to engage potential customers from the 300+ early-stage companies that attend RESI, plus the brand visibility, make RESI ideal for service providers catering to these companies, developing technologies in drugs, devices, diagnostics and digital health.

RESI offers different levels of sponsorship to service providers, who can target prospective clients and maximize their brand visibility. Options range from exhibiting at RESI to hosting a sponsored workshop during the conference.

RESI-Boston-2023-September-1100px-w

Enhancing Efficiency and Strategy of Investor Outreach

3 Aug

By Cameron Hurlburt, Manager of Business Development – West Coast (US), LSN

Life Science Nation (LSN) has implemented a new pricing model for our Investor and Licensing Partner Database. This database contains 3K+ investor firms, with specific interests in the early-stage life science sector, across 10 categories of investors* and licensing partners, including 10K+ contacts. Searches can be executed through specific filters including but not limited to, sector, subsector, indication, and phase of development. The information presented in the database is obtained directly from each company through 1:1 interviews with investor research analysts at LSN and updated regularly.  This is a valuable resource for companies looking to establish their Global Target List and execute their fundraising journey.

*10 categories of investors:

  • Angel Groups
  • Corporate Venture Capital
  • Endowments/Foundations
  • Family Office/Private Wealth Funds
  • Government Organizations
  • Hedge Funds
  • Institutional Alternative Investors
  • Large Pharma/ Biotech Companies
  • Private Equity
  • Venture Capital

The prior pricing model was $4.5K for 6 months or $7K for 1 year. Since most companies that wish to utilize our database are early-stage and pre-revenue, LSN aimed to transition the hefty up-front cost to a monthly, lower-cost plan. Our new subscription options are shown below:

Standard:

  • $300/month or $3K/year up-front
  • Minimum 6 months commitment

Premier (Recommended):

  • $500/month or $5K/year up-front
  • Includes 50% off ALL RESI Registrations for the duration of the subscription (excludes IPC)
  • Minimum 6 months commitment

To learn more about this database, please contact your Business Development Manager at Life Science Nation and we would be happy to walk you through the database and help answer any questions or concerns you may have!

Life Science Nation Business Development Team
International
East Coast (USA) & China
Midwest (USA)
& Canada
West Coast  (USA)
Cam_Headshot_new
Greg Mannix
Vice President International Business Development
Book a Meeting
Email Me
Candice He
VP, Business Development & Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Cameron Hurlburt
Manager of Business Development
Book a Meeting
Email Me

RESI-Boston-2023-September-1100px-w

← Older Entries
Newer Entries →